Peramivir Treatment Response in Adults Hospitalized for Influenza-associated Lower Respiratory Tract Infections

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (81 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-03-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: placebo controlledtolerabilityintravenoussafety andchemotherapy
  Phrases that lowered it: influenzadiseasessubjectsopenlabel
• Sponsor's past termination rate: 12.9% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Design: parallel (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Trials the sponsor started in the prior 2 years: 49 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Disease area, respiratory: Yes (raises risk) · Disease area
• Phase: 2/3 (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area
• Collaborators: 1 (raises risk) · Design
• Sponsor's past trials: 62 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza NCT02635724 · started 2015 · scored riskier than 55% of active trials completed
• A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza NCT00705406 · started 2008 · scored riskier than 30% of active trials completed
• Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza NCT00610935 · started 2008 · scored riskier than 29% of active trials terminated
• Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza NCT02369159 · started 2015 · scored riskier than 24% of active trials completed
• Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza NCT00957996 · started 2009 · scored riskier than 81% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.